The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Optimizing the combination of ibrutinib plus venetoclax in CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the efficacy of combining ibrutinib and venetoclax in treating chronic lymphocytic leukemia (CLL). Five-year follow-up data from the CAPTIVATE trial (NCT02910583) reveals a progression-free survival (PFS) rate of 70%, with high-risk patients also showing high PFS rates. Dr Scarfò notes ongoing efforts to manage potential cardiotoxicities associated with ibrutinib, highlighting a fixed-duration treatment schedule that allows for treatment-free intervals. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly, Merck; Speaker bureau: OctaPharma.
